These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 31389318)

  • 1. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Highly Active Antiretroviral Therapy on Renal Function and Renal Phosphate Handling in African Adults with Advanced HIV and CKD.
    Adedeji TA; Adebisi SA; Adedeji NO; Biliaminu SA; Olanrewaju TO
    Infect Disord Drug Targets; 2019; 19(1):88-100. PubMed ID: 30027856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
    Chetty T; Thorne C; Coutsoudis A
    PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
    Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
    Arribas JR; Pozniak AL; Gallant JE; Dejesus E; Gazzard B; Campo RE; Chen SS; McColl D; Holmes CB; Enejosa J; Toole JJ; Cheng AK
    J Acquir Immune Defic Syndr; 2008 Jan; 47(1):74-8. PubMed ID: 17971715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
    Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
    J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
    Campbell TB; Smeaton LM; Kumarasamy N; Flanigan T; Klingman KL; Firnhaber C; Grinsztejn B; Hosseinipour MC; Kumwenda J; Lalloo U; Riviere C; Sanchez J; Melo M; Supparatpinyo K; Tripathy S; Martinez AI; Nair A; Walawander A; Moran L; Chen Y; Snowden W; Rooney JF; Uy J; Schooley RT; De Gruttola V; Hakim JG;
    PLoS Med; 2012; 9(8):e1001290. PubMed ID: 22936892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes.
    Caniglia EC; Zash R; Jacobson DL; Diseko M; Mayondi G; Lockman S; Chen JY; Mmalane M; Makhema J; Hernán MA; Shapiro RL
    AIDS; 2018 Jan; 32(1):113-120. PubMed ID: 29112066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
    Erlandson KM; Fiorillo SP; Cardoso SW; Riviere C; Sanchez J; Hakim J; Kumarasamy N; Badal-Faesen S; Lalloo U; Kumwenda J; Campbell TB; Brown TT
    AIDS Res Hum Retroviruses; 2017 Sep; 33(9):929-934. PubMed ID: 28403619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
    Martínez E; Ribera E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Larrousse M; Curran A; Negredo E; Arterburn S; Ferrer P; Álvarez ML
    HIV Med; 2015 Jul; 16(6):370-4. PubMed ID: 25496141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
    Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
    Bulteel N; Bansi-Matharu L; Churchill D; Dunn D; Bibby D; Hill T; Sabin C; Nelson M; ;
    J Infect; 2014 Jan; 68(1):77-84. PubMed ID: 24055802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
    Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
    Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.
    Chi BH; Mwango A; Giganti MJ; Sikazwe I; Moyo C; Schuttner L; Mulenga LB; Bolton-Moore C; Chintu NT; Sheneberger R; Stringer EM; Stringer JS
    J Acquir Immune Defic Syndr; 2011 Dec; 58(5):475-81. PubMed ID: 21857354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
    McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE
    J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
    Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM
    BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Petlo C; Lockman S; Makhema J; Shapiro RL
    JAMA Pediatr; 2017 Oct; 171(10):e172222. PubMed ID: 28783807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
    Tang MW; Kanki PJ; Shafer RW
    Clin Infect Dis; 2012 Mar; 54(6):862-75. PubMed ID: 22357809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.